INMB (INmune Bio) Net Margin %: 0.00% (As of Mar. 2026)


INMB INmune Bio Inc INMB
53 GF Score
Price $1.42
GF Value $1.83
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is INmune Bio Net Margin %?

INmune Bio INMB -5.02% 53 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates INMB with a GF Score™ of 53/100 and a GF Value™ of $1.83 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 946 Biotechnology companies, INmune Bio ranks worse than 105708.14% on this metric.

Net margin is calculated as Net Income divided by its Revenue. INmune Bio's Net Income for the three months ended in Mar. 2026 was $-5.41 Mil. INmune Bio's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, INmune Bio's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for INmune Bio's Net Margin % or its related term are showing as below:


INMB's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.815
* Ranked among companies with meaningful Net Margin % only.

INmune Bio  (NAS:INMB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

INmune Bio Net Margin % Related Terms

INmune Bio Net Margin % Historical Data

* Premium members only.

The historical data trend for INmune Bio's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

INmune Bio Net Margin % Chart

INmune Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16,762.43 -7,299.20 -19,360.00 -300,585.71 -91,866.00

INmune Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19,478.00 0.00 0.00 0.00 0.00

INMB vs GRDX, VERU, ABVC: Net Margin % Comparison

For the Biotechnology subindustry, INmune Bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

INmune Bio Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's Net Margin % distribution charts can be found below:

* The bar in red indicates where INmune Bio's Net Margin % falls into.


INMB
53GF Score
INmune Bio Inc INMB
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

INmune Bio Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

INmune Bio's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-45.933/0.05
=-91,866.00 %

INmune Bio's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-5.407/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
INmune Bio (INMB) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on INmune Bio and its competitors. According to the industry distribution chart, INmune Bio ranks #999999 out of 946 companies in the Biotechnology industry.
Is INmune Bio's Net Margin % too high?
INmune Bio's current Net Margin % is 0.00%. Based on the distribution chart, INmune Bio ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, INmune Bio has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's Net Margin % compare to GRDX and VERU?
According to the Biotechnology industry distribution chart, INmune Bio ranks #999999 out of 946 companies for Net Margin %. This places INmune Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on INmune Bio and its competitors. INmune Bio's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.83, compared to a current price of $1.42 — trading 22.4% below its estimated fair value. The current Net Margin % is 0.00%. INmune Bio's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For INmune Bio (INMB), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is INmune Bio (INMB) Overvalued in 2026?

Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued. The current stock price of $1.42 is trading 22.4% below its estimated GF Value™ of $1.83. GuruFocus considers INmune Bio to be Modestly Undervalued.

Key valuation signals for INMB:

  • Net Margin %: 0.00%
  • GF Value™: $1.83 vs. price of $1.42 (22.4% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

INmune Bio Business Description

Address 225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
53GF Score

Get the complete analysis for INMB

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.42
Price
$1.83
GF Value